Discover 707 paid clinical trials in Olathe, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 707
Active & Responsive
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Location: Lenexa KS, West Des Moines IA, Joliet IL, Lemont IL,
Sponsor: EyeBiotech Ltd.
Sex: All
Age: 50+
Code: NCT07496567
Phase2, Phase3, Recruiting
Active & Responsive
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
for
Overweight, Obesity
Location: Overland Park KS, Montreal, Cypress CA
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18 - 65
Code: NCT07395687
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
for
Extensive Stage Lung Small Cell Carcinoma,
Location: Overland Park KS, Fairway KS, Westwood KS,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06287775
Phase1, Phase2, Recruiting
Active & Responsive
Safety of MOON101 for the Treatment of Peanut Allergy
for
Peanut Allergy
Location: Overland Park KS, Little Rock AR, Ann Arbor MI,
Sponsor: Moonlight Therapeutics, Inc.
Sex: All
Age: 4 - 55
Code: NCT07580898
Phase1, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
for
Percutaneous Coronary Intervention,
Location: Overland Park KS, Columbia MO, Wichita KS, Lincoln NE,
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06909565
Recruiting
Active & Responsive
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for
Cardiovascular Disease
Location: Overland Park KS, Kansas City KS, Kansas City MO,
Sponsor: Amgen
Sex: All
Age: 50 - 70+
Code: NCT07136012
Phase3, Recruiting
Active & Responsive
Assessment of CCM in HF With Higher Ejection Fraction
for
Heart Failure, Heart Failure With Preserved Ejection Fraction,
Location: Overland Park KS, Kansas City KS, Kansas City MO,
Sponsor: Impulse Dynamics
Sex: All
Age: 18+
Code: NCT05064709
Recruiting
Active & Responsive
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
for
Chronic Migraine
Location: Overland Park KS, Omaha NE, City of Saint Peters MO,
Sponsor: Merz Therapeutics GmbH
Sex: All
Age: 18+
Code: NCT07018713
Phase3, Recruiting
Active & Responsive
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
for
Episodic Migraine
Location: Overland Park KS, Omaha NE, City of Saint Peters MO,
Sponsor: Merz Therapeutics GmbH
Sex: All
Age: 18+
Code: NCT07018700
Phase3, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
for
NASH - Nonalcoholic Steatohepatitis,
Location: Kansas City MO, Topeka KS, Columbia MO, St Louis MO,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06528314
Phase3, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: Kansas City MO, Topeka KS, Columbia MO, St Louis MO,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
for
Obesity, Overweight
Location: Kansas City MO, Newton KS, Norman OK, Dallas TX,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07684235
Phase3, Recruiting
Active & Responsive
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity